Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.40 |
| ▸ | F9 | P00740 | 2/20 | 0.37 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095329 | 1.00 | ROCK2 (0.42) | ROCK2ROCK1GRM4F9SREBF2 | |
| SCHEMBL14642427 | 0.88 | ROCK2 (0.45) | ROCK2ROCK1GRM4F9 | |
| Hydrochloric Acid SCHEMBL1096782 | 0.84 | ROCK2 (0.46) | ROCK2ROCK1GRM4F9 | |
| Hydrochloric Acid SCHEMBL1096786 | 0.84 | ROCK2 (0.46) | ROCK2ROCK1GRM4F9 | |
| SCHEMBL16084818 | 0.83 | ROCK2 (0.44) | ROCK2ROCK1GRM4F9 | |
| SCHEMBL16079003 | 0.81 | ROCK2 (0.48) | ROCK2ROCK1GRM4F9 | |
| SCHEMBL13763800 | 0.81 | GRM4 (0.35) | GRM4F9SREBF2JAK2HDAC4 | |
| SCHEMBL1105175 | 0.80 | ROCK2 (0.46) | ROCK2ROCK1GRM4F9 | |
| SCHEMBL8327841 | 0.79 | CTSS (0.41) | ROCK2ROCK1CTSSCTSKHDAC4 | |
| Verosudil SCHEMBL16036842 | 0.79 | ROCK2 (0.66) | ROCK2ROCK1GRM4F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546239-B1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2546238-A1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546237-A1 | 7-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546239-A1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2252589-B1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-8153654-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | COQ8A, MAP3K7, PRKG2 | ROCK2 214/4885ROCK1 304/4885GRM4 2208/4885 |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | COQ8A, MAP3K7, PRKG2 | ROCK2 214/4885ROCK1 304/4885GRM4 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.